OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2025
All the vital news, analysis, and commentary curated by our industry experts.
The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth during the forecast period. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy. Though initially effective, toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is rapidly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of newer immunotherapies, specifically, PD-1 checkpoint modulators, of which five are expected to launch by 2025. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.
Key Questions Answered
How will the bladder cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015–2025?
What are the most promising late-stage pipeline drugs in bladder cancer?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the unmet needs in bladder cancer treatment management?
What drivers and barriers will affect bladder cancer therapeutics sales in the 7MM over the forecast period?
Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline Bladder cancer market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the bladder cancer therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Eli Lilly & Co.
FKD Therapies Oy
Merck & Co.
Pierre Fabre Medicament
Table of Contents
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Bladder Cancer: Executive Summary
2.1 Bladder Cancer Market in the 7MM Expected To Triple in Size From 2015 to 2025
2.2 Big Pharma Focuses on Label Expansion, While Smaller Companies Focus on Developing Drugs with Novel Mechanisms of Action
2.3 The Levels of Unmet Need Remain High Across Bladder Cancer Settings
2.4 Pipeline Agents Will Reduce Unmet Need, but Opportunities Remain
2.5 NMIBC Settings Are Not Expected to Change Significantly, While PD-1 Checkpoint Inhibitors Are Expected to Gain Stronghold in Advanced Disease Settings
2.6 What Do Physicians Think?
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
3.5 Quality of Life
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.2 Relative Survival
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for Bladder Cancer (2015–2025)
4.5.1 Diagnosed Incident Cases of Bladder Cancer
4.5.2 Age-Specific Diagnosed Incident Cases of Bladder Cancer
4.5.3 Sex-Specific Diagnosed Incident Cases of Bladder Cancer
4.5.4 Age-Standardized Diagnosed Incidence Rates of Bladder Cancer
4.5.5 Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis
4.5.6 Five-Year Diagnosed Prevalent Cases of Bladder Cancer
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Current Treatment Options
5.2 Diagnosis and Treatment
5.2.2 Treatment Guidelines and Leading Prescribed Drugs
5.3 Clinical Practice
5.4 Product Profiles – Major Brands, Immunotherapies
5.4.1 Bacillus Calmette-Guérin (BCG)
5.4.2 Tecentriq (atezolizumab)
5.4.3 Opdivo (nivolumab)
5.5 Product Profiles – Major Brands, Chemotherapies
5.5.1 GemCis (gemcitabine/cisplatin)
5.5.2 Mitomycin C
5.5.3 Valstar (valrubicin)
5.5.4 Javlor (vinflunine ditartrate)
6 Unmet Needs Assessment and Opportunity Analysis
6.2 Improved Treatments for Patients with BCG-Relapsed/Refractory NMIBC
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.3 Prevention of Disease Progression in Patients with NMIBC
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.4 Therapies for Advanced Disease Beyond Immune Checkpoint Inhibitors
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.5 Predictive Biomarkers to Drive Drug Discovery
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.6 Improved Diagnostic Methods
6.6.1 Unmet Need
6.6.2 Gap Analysis
7 Research and Development Strategies
7.1.1 Drug Development by Small Pharmaceutical Companies
7.1.2 Intravesical Approaches for NMIBC May Give Way to Systemic Approaches in the Future
7.1.3 Identification of Prognostic Markers for PD-1 Checkpoint Inhibitors
7.1.4 Conversion of PD-1 Checkpoint Inhibitor Nonresponders to Responders
7.2 Clinical Trial Design
7.2.1 Registrational Studies: Open-Label, Non-Comparative Trial Designs Still Prevalent
7.2.2 Variability of Trial Endpoints in Both the NMIBC and Advanced Disease Settings
8 Pipeline Assessment
8.2 Promising Drugs in Clinical Development
8.2.2 Instiladrin (rAD-Interferon (IFN)/Syn3)
8.2.3 Vicinium (oportuzumab monatox)
8.2.5 Cyramza (ramucirumab)
8.2.6 PD-1 Immune Checkpoint Inhibitors
8.3 Innovative Early-Stage Approaches
8.3.2 Cometriq (cabozantinib)
8.3.4 IMMU-132 (sacituzumab govitecan)
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top-Line 10-Year Forecast
10.4 Forecasting Methodology
10.4.1 Diagnosed Bladder Cancer Patients
10.4.2 Percent Drug-Treated Patients
10.4.3 Drugs Included in Each Therapeutic Class
10.4.4 Launch and Patent Expiry Dates
10.4.5 General Pricing Assumptions
10.4.6 Individual Drug Assumptions
10.4.7 Generic Erosion
10.4.8 Pricing of Pipeline Agents
10.5 Primary Research – KOLs Interviewed for this Report
10.6 Primary Research – Prescriber Survey
10.7 About the Authors
10.7.2 Therapy Area Director
10.7.4 Managing Epidemiologist
10.7.5 Global Director of Therapy Analysis and Epidemiology
10.7.6 Global Head and EVP of Healthcare Operations and Strategy
10.8 About GlobalData
10.9 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.